Desmoglein‑1 was detected in immersion fixed paraffin-embedded sections of human skin using Goat Anti-Human Desmoglein‑1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF944) at 15 µg/mL overnight at 4 ...read more
Mouse myeloma cell line NS0-derived recombinant human Desmoglein‑1 extracellular domain Glu50-His545 Accession # Q02413
Detects human Desmoglein‑1 in direct ELISAs and Western blots. In direct ELISAs, less than 5% cross‑reactivity with recombinant human (rh) Desmoglein-2 is observed and less than 1% cross-reactivity with rhDesmoglein-3, rhDesmoglein-4, and recombinant mouse Desmoglein-1 alpha is observed.
Immunogen affinity purified
Test in a species/application not listed above to receive a full credit towards a future purchase.
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Immunogen affinity purified
Reconstitute at 0.2 mg/mL in sterile PBS.
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for Desmoglein-1 Antibody [Unconjugated] - Propeptide
Cadherin family member 4
Desmosomal glycoprotein 1
Pemphigus foliaceus antigen
Desmoglein-1 is one of three members of the desmoglein subfamily of calcium-dependent cadherin cell adhesion molecules. Together with desmocollins, another subfamily within the cadherin superfamily, the desmoglein isoforms form the adhesive components of desmosomes, the cell-cell adhesive structures that are found in epithelial cells. Human Desmoglein-1 is a type I transmembrane glycoprotein of 1049 amino acid (aa) residues with a 23 aa signal peptide and a 26 aa propeptide. It differs from other classic cadherins by having four instead of five cadherin repeat domains in its extracellular region, and a much larger cytoplasmic region containing five desmoglein repeat domains which share homology with the cadherin repeats. Instead of having the HAV adhesion motif found in type I cadherins, Desmoglein-1 has R/YAL as the adhesion motif on its amino-terminal cadherin repeat. The cytoplasmic tail of Desmoglein-1 interacts with desmoplakins, plakoglobin and plakophilins. In turn, these proteins link the Desmoglein-1 with the intermediate filaments. Desmoglein-1 has been shown to be important in establishing cell-cell adhesion and function in the epidermis. In the autoimmune skin disease pemphigus foliaceus, autoantibodies to Desmoglein-1 can cause the loss of keratinocyte adhesion resulting in blisters.
Nollet, R. et al. (2000) J. Mol. Biol. 299:551.
Elias, P. et al. (2001) J. Cell Biol. 153:243.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our Desmoglein-1 Antibody [Unconjugated] - Propeptide and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.